The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards
-
November 5, 2025
-
0 min
Clinical Report: Advances and Award Recognitions at the 51st EBMT Annual Conference
Overview
The 51st Annual Conference of the European Society for Blood and Marrow Transplantation highlighted significant advances in stem cell transplantation, immunotherapy, and graft-versus-host disease (GvHD) management. Key findings include improved outcomes with haploidentical transplantation, novel gene therapies, and effective treatments for severe GvHD.
Background
The European Society for Blood and Marrow Transplantation (EBMT) annual meeting serves as a premier platform for presenting cutting-edge research in hematopoietic stem cell transplantation and cellular therapies. This conference showcased studies on allogeneic and autologous transplantation, gene editing, immunotherapy, and complications such as GvHD and veno-occlusive disease (VOD). Recognition of Van Bekkum Award recipients underscored outstanding contributions to the field. The meeting also emphasized translational research bridging laboratory findings with clinical applications.
Data Highlights
| Study Topic | Key Outcome | Location |
|---|---|---|
| Haploidentical SCT in children | Improved survival in bad-risk AML with KIR epitope incompatibility | Tübingen, Erlangen, Perugia, Italy |
| Autologous transplantation with serum-free retroviral gene marking | First results in chronic myeloid leukemia | Freiburg, Germany |
| Mesenchymal stem cells for severe GvHD | Effective treatment of acute and chronic GvHD | Stockholm, Genoa, Pavia, Leiden |
| Defibrotide for hepatic VOD prevention | Significant reduction in VOD-associated complications in children | Multicenter European study |
| TCR gene editing immunotherapy | Effective leukemia treatment without GvHD development | Milan, Richmond, Seattle |
| CAR T-cell therapy targeting CD19 | Complete responses and long-term persistence without GVHD | Philadelphia, USA |
Key Findings
- Haploidentical stem cell transplantation with KIR epitope incompatibility improves survival in high-risk acute myeloid leukemia patients.
- Gene marking and retroviral techniques enable autologous transplantation advances in chronic myeloid leukemia.
- Mesenchymal stem cells show promise in treating severe acute and extensive chronic graft-versus-host disease.
- Defibrotide prophylaxis significantly reduces hepatic veno-occlusive disease and related complications in high-risk pediatric patients.
- T-cell receptor gene editing provides effective leukemia immunotherapy without inducing graft-versus-host disease.
- CD19-targeted CAR T-cell therapy achieves significant in vivo proliferation, complete remission, and long-term persistence in relapsed/refractory leukemia without GVHD.
Clinical Implications
These findings support the integration of haploidentical transplantation strategies with KIR mismatch considerations to improve outcomes in AML. The use of mesenchymal stem cells and defibrotide offers effective management options for severe GvHD and VOD, respectively. Advances in gene editing and CAR T-cell therapies provide promising immunotherapeutic approaches that minimize GvHD risk while enhancing anti-leukemia efficacy.
Conclusion
The 51st EBMT Annual Conference highlighted transformative advances in transplantation and cellular therapies, emphasizing improved survival, reduced complications, and innovative immunotherapies. These developments pave the way for enhanced patient outcomes in hematologic malignancies and transplant-related complications.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
